Aptevo Therapeutics Inc (APVO) Stock Analysis

AI analysis of Aptevo Therapeutics Inc (APVO)

Sell

Aptevo Therapeutics is not a good buy right now due to its extremely low RSI of 19.049, indicating oversold conditions, and a staggering year-to-date change of -86.80%. The stock has significant financial challenges, including a reported EPS of -40.11, which is far below expectations. The main risk is its forward P/E of 3.8895, which suggests that while the stock may be undervalued, the company is struggling to generate revenue, as evidenced by total revenue of $0.00 for multiple quarters. The lack of positive cash flow and ongoing losses indicate that investors should be cautious before considering a purchase.

Analyst Ratings (1)

Buy

1 Buy

0 Hold

0 Sell

Current: 1.24

Low

—

Average

—

High

—

Roth Capital

Buy

$21

2026-09-03

Roth Capital

2026-09-03

Price Target

$21

Buy

Roth MKM

Strong Buy

$8

2024-09-23

Roth MKM

2024-09-23

Price Target

$8

Strong Buy

Piper Sandler

Buy

$20

2022-05-13

Piper Sandler

2022-05-13

Price Target

$20

Buy

Roth Capital

Strong Buy

—

2021-05-28

Roth Capital

2021-05-28

Price Target

—

Strong Buy

Piper Sandler

Buy

—

2020-11-11

Piper Sandler

2020-11-11

Price Target

—

Buy

See All Ratings

Valuation Metrics

The current forward P/E ratio for Aptevo Therapeutics Inc (APVO) is 3.89, compared to its 5-year average forward P/E of 0.57.

Forward P/E

Overvalued

5Y Average P/E

0.57

Current P/E

3.89

Overvalued

2.79

Undervalued

-1.65

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Fair

5Y Average P/S

0.77

Current P/S

0.00

Overvalued

3.09

Undervalued

-1.55

Alphio AI Price Scenarios for APVO

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%APVO

$3.29

Scenario price

B

Base

Base · 50%APVO

$2.81

Scenario price

B

Bear

Bear · 25%APVO

$2.54

Scenario price

APVO FAQ — answered by Alphio AI

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Aptevo Therapeutics is not a good buy right now due to its extremely low RSI of 19.049, indicating oversold conditions, and a staggering year-to-date change of -86.80%. The stock has significant financial challenges, including a reported EPS of -40.11, which is far below expectations. The main risk is its forward P/E of 3.8895, which suggests that while the stock may be undervalued, the company is struggling to generate revenue, as evidenced by total revenue of $0.00 for multiple quarters. The lack of positive cash flow and ongoing losses indicate that investors should be cautious before considering a purchase.

1 analysts cover APVO: 1 rate it Buy, 0 Hold and 0 Sell.